Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor
Hero Background
English
Chinese
French
Japanese
Korean
German
Spanish

Veterinary Pain Management Market Size

ID: MRFR/HC/4505-CR
200 Pages
Rahul Gotadki
April 2025

Global Veterinary Pain Management Market Research Report By Product Type (Non-Steroidal Anti-Inflammatory Drugs, Opioids, Analgesics, Adjuvant Analgesics), By Animal Type (Dogs, Cats, Horses, Livestock), By Route of Administration (Oral, Injections, Transdermal, Topical), By End User (Veterinary Hospitals, Clinics, Research Institutes) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) -Forecast to 2035

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Veterinary Pain Management Market Infographic
Request Free Sample
Purchase Options
Compare License
Summary Table of Contents Segmentation Methodology Download PDF

Veterinary Pain Management Size

Veterinary Pain Management Market Growth Projections and Opportunities

Over the past 35 years, the United States has witnessed a notable increase in pet ownership, a trend that has been paralleled by the remarkable growth of the pet insurance industry. According to statistics gathered by Forbes Advisor, the surge in pet ownership is not only changing the landscape of American households but also influencing the dynamics of veterinary care. The symbiotic relationship between the rise in pet ownership and the expanding pet insurance sector is reshaping the way pet owners approach the healthcare needs of their furry companions, particularly in the realm of pain management.

Pet insurance has emerged as a crucial financial safeguard for pet owners, providing protection against the exorbitant costs associated with unexpected veterinary expenses. This is particularly significant in situations where pets face injuries or illnesses, requiring immediate and often costly medical attention. Forbes Advisor's data highlights that the average monthly cost of pet insurance for dogs stands at USD 44, while cat owners incur an average cost of USD 30 per month. This financial buffer not only eases the burden on pet owners but also ensures that pets receive prompt and comprehensive medical care without financial constraints hindering their well-being.

The surge in pet insurance adoption is closely linked to the growing awareness among pet owners about the importance of proactive healthcare measures for their animal companions. As pets increasingly become integral members of families, the demand for comprehensive healthcare solutions, including insurance coverage, has seen a significant upswing. This trend is evident in the rising expenditure on pets in the United States.

In 2022, Americans spent a staggering USD 136.8 billion on their dogs alone, marking a noteworthy 10.68% increase from the previous year's spending of USD 123.6 billion. This substantial expenditure encompasses various aspects of pet care, including USD 58.1 billion on pet food and treats, USD 31.5 billion on supplies, live animals, and over-the-counter medications, USD 35.9 billion on veterinary care, and USD 11.4 billion on other services such as boarding, grooming, pet insurance, and training.

The significant allocation of funds to veterinary care, combined with the rise in pet insurance coverage, is poised to have a profound impact on the global veterinary pain management market. As pet owners increasingly prioritize the health and well-being of their beloved animals, the demand for advanced pain management solutions is expected to surge. This evolving landscape presents opportunities for innovation and growth within the veterinary pain management sector, as stakeholders respond to the increasing expectations of pet owners for comprehensive and accessible healthcare solutions for their furry family members.

In conclusion, the intertwining trends of escalating pet ownership, the rise of the pet insurance industry, and the surge in pet-related expenditure underscore a fundamental shift in the way pets are cared for and treated in contemporary society. As pet owners actively seek financial protection through insurance coverage and invest significantly in the well-being of their animals, the global veterinary pain management market is poised for substantial growth. This trend not only reflects a commitment to providing the best possible care for pets but also signifies a lucrative market opportunity for stakeholders in the veterinary healthcare sector. As pet insurance continues to gain prominence, the veterinary pain management market is well-positioned to evolve in tandem, ensuring that pets lead healthy, pain-free lives with the support of accessible and comprehensive healthcare solutions.

Veterinary Pain Management Market Size Graph
Author
Author Profile
Rahul Gotadki
Research Manager

He holds an experience of about 9+ years in Market Research and Business Consulting, working under the spectrum of Life Sciences and Healthcare domains. Rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. His expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc.

Get In Touch

Leave a Comment

FAQs

What is the projected market valuation of the Veterinary Pain Management Market by 2035?

<p>The Veterinary Pain Management Market is projected to reach approximately 4.184 USD Billion by 2035.</p>

What was the market valuation of the Veterinary Pain Management Market in 2024?

<p>In 2024, the market valuation of the Veterinary Pain Management Market was 2.11 USD Billion.</p>

What is the expected CAGR for the Veterinary Pain Management Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Veterinary Pain Management Market during the forecast period 2025 - 2035 is 6.42%.</p>

Which product type segment is anticipated to have the highest valuation by 2035?

<p>The Non-Steroidal Anti-Inflammatory Drugs segment is anticipated to reach approximately 1.68 USD Billion by 2035.</p>

How does the market for pain management in dogs compare to that in cats by 2035?

<p>By 2035, the market for pain management in dogs is expected to reach around 1.68 USD Billion, while the market for cats is projected to reach approximately 1.26 USD Billion.</p>

What are the key routes of administration for veterinary pain management products?

<p>The key routes of administration include Oral, Injections, Transdermal, and Topical, with Oral expected to reach 1.68 USD Billion by 2035.</p>

Which end user segment is projected to dominate the Veterinary Pain Management Market by 2035?

<p>Veterinary Hospitals are projected to dominate the market, with an expected valuation of approximately 1.68 USD Billion by 2035.</p>

Who are the leading companies in the Veterinary Pain Management Market?

<p>Key players in the Veterinary Pain Management Market include Zoetis, Boehringer Ingelheim, Elanco Animal Health, and Merck Animal Health.</p>

What is the expected growth trend for the Opioids segment in the Veterinary Pain Management Market?

<p>The Opioids segment is expected to grow to approximately 1.26 USD Billion by 2035, indicating a strong upward trend.</p>

How does the market for livestock pain management products compare to that for horses by 2035?

<p>By 2035, the market for livestock pain management products is projected to reach around 0.44 USD Billion, while the market for horses is expected to reach approximately 0.84 USD Billion.</p>

Market Summary

As per Market Research Future analysis, the Veterinary Pain Management Market was estimated at 2.11 USD Billion in 2024. The Veterinary Pain Management industry is projected to grow from 2.246 USD Billion in 2025 to 4.184 USD Billion by 2035, exhibiting a compound annual growth rate (CAGR) of 6.42% during the forecast period 2025 - 2035

Key Market Trends & Highlights

The Veterinary Pain Management Market is experiencing significant growth driven by advancements in technology and increasing awareness of animal welfare.

  • The market is witnessing a rise in alternative therapies as pet owners seek holistic pain management solutions. Technological integration is enhancing the efficacy of pain management products, particularly in North America. The focus on animal welfare is driving demand for effective pain management solutions, especially for dogs, which represent the largest segment. Key market drivers include the growing demand for pain management solutions and increased awareness of animal welfare, particularly in the context of rising chronic conditions in pets.

Market Size & Forecast

2024 Market Size 2.11 (USD Billion)
2035 Market Size 4.184 (USD Billion)
CAGR (2025 - 2035) 6.42%
Largest Regional Market Share in 2024 North America

Major Players

Zoetis (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Merck Animal Health (US), Vetoquinol (FR), Ceva Santé Animale (FR), Dechra Pharmaceuticals (GB), Virbac (FR), PetIQ (US), MediVet (AU)

Market Trends

The veterinary pain management market trends indicate that the Veterinary Pain Management Market is currently experiencing a notable evolution, driven by increasing awareness of animal welfare and advancements in veterinary medicine. As pet ownership continues to rise, there is growing demand across the broader veterinary pain management market for effective solutions for both companion animals and livestock. This market encompasses a variety of products, including analgesics, anti-inflammatory medications, and alternative therapies, which are becoming more widely accepted among veterinarians and pet owners alike. The integration of innovative technologies is further shaping the global veterinary pain management market landscape.

Moreover, the Veterinary Pain Management Market is likely to benefit from ongoing research and development efforts aimed at discovering new therapeutic options within the expanding veterinary pain management drugs market. Collaboration between pharmaceutical companies and veterinary professionals will remain key in strengthening the veterinary pain management market forcast outlook.

Rise of Alternative Therapies

There is a growing trend towards the use of alternative therapies in the veterinary pain management market, contributing to evolving treatment strategies and influencing overall veterinary pain management market trends. These methods are often perceived as complementary to traditional pharmaceuticals, providing holistic approaches to pain relief.

Technological Integration

The integration of technology into veterinary practices is transforming strategies across the global veterinary pain management market, enabling more personalized care and improved monitoring capabilities. This trend suggests a shift towards more personalized care, allowing for real-time monitoring of an animal's condition.

Increased Focus on Animal Welfare

There is an increasing emphasis on animal welfare within the veterinary pain management market, driving innovation in treatment approaches and expanding the veterinary pain management drugs market. This heightened awareness is driving demand for effective pain management solutions that prioritize the comfort and quality of life of animals. As a result, veterinary professionals are more likely to advocate for comprehensive pain management protocols.

Veterinary Pain Management Market Market Drivers

Advancements in Veterinary Medicine

The Veterinary Pain Management Market is significantly influenced by advancements in veterinary medicine. Innovations in drug formulations, delivery methods, and diagnostic tools are enhancing the ability of veterinarians to manage pain effectively. For instance, the introduction of long-acting analgesics and novel drug delivery systems has improved pain control in various animal species. Furthermore, the integration of technology, such as telemedicine and wearable devices, allows for better monitoring of pain levels in pets. According to recent estimates, the veterinary pharmaceuticals segment is projected to grow at a compound annual growth rate of 7% over the next five years. This growth reflects the ongoing commitment to improving pain management strategies within the Veterinary Pain Management Market.

Increased Awareness of Animal Welfare

The Veterinary Pain Management Market is benefiting from a heightened awareness of animal welfare among pet owners and veterinarians alike. As society places greater emphasis on the ethical treatment of animals, there is a growing expectation for veterinarians to provide comprehensive pain management solutions. This shift in perspective is leading to more proactive approaches in addressing pain in animals, particularly in surgical and post-operative care. Research indicates that nearly 70% of veterinarians report an increase in client inquiries regarding pain management options. This trend is likely to foster a more compassionate approach to veterinary care, ultimately driving growth in the Veterinary Pain Management Market as stakeholders prioritize the well-being of animals.

Growing Demand for Pain Management Solutions

The Veterinary Pain Management Market is experiencing a notable increase in demand for effective pain management solutions. Pet owners are becoming increasingly aware of the importance of alleviating pain in their animals, leading to a rise in consultations with veterinarians. This trend is supported by data indicating that approximately 60% of pet owners consider pain management a critical aspect of their pets' healthcare. As a result, veterinary practices are expanding their offerings to include a variety of pain management options, such as analgesics, anti-inflammatory medications, and alternative therapies. This growing demand is likely to drive innovation and investment in the Veterinary Pain Management Market, as companies strive to meet the evolving needs of both veterinarians and pet owners.

Rising Incidence of Chronic Conditions in Pets

The Veterinary Pain Management Market is experiencing growth due to the rising incidence of chronic conditions in pets. Conditions such as arthritis, cancer, and obesity are becoming increasingly prevalent among companion animals, necessitating effective pain management strategies. Data suggests that approximately 20% of dogs and 30% of cats are affected by arthritis, leading to a significant demand for pain relief solutions. As pet owners seek to improve their animals' quality of life, veterinarians are compelled to adopt comprehensive pain management protocols. This trend is expected to drive the expansion of the Veterinary Pain Management Market, as more products and services are developed to address the specific needs of pets suffering from chronic pain.

Regulatory Support for Pain Management Products

The Veterinary Pain Management Market is also shaped by regulatory support for pain management products. Regulatory agencies are increasingly recognizing the importance of effective pain management in veterinary medicine, leading to streamlined approval processes for new analgesics and therapies. This supportive regulatory environment encourages pharmaceutical companies to invest in research and development, resulting in a wider array of pain management options for veterinarians. For example, recent changes in regulations have facilitated the introduction of new formulations that are safer and more effective for various animal species. As a consequence, the Veterinary Pain Management Market is likely to see an influx of innovative products that enhance pain management practices.

Market Segment Insights

By Product Type: Non-Steroidal Anti-Inflammatory Drugs (Largest) vs. Opioids (Fastest-Growing)

The Veterinary Pain Management Market segments around product types reveal non-steroidal anti-inflammatory drugs (NSAIDs) as the dominant force, holding the largest market share thanks to their established efficacy in managing pain and inflammation in animals. These drugs are widely utilized in various veterinary practices, making them readily available and trusted by professionals. Opioids, meanwhile, are emerging rapidly due to increasing awareness of their effectiveness for managing severe pain in animals and are becoming a more accepted option by veterinarians, reflecting a significant shift in treatment approaches.

NSAIDs (Dominant) vs. Opioids (Emerging)

Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) continue to be the dominant product type in the veterinary pain management landscape, primarily used for their anti-inflammatory properties and pain relief across various species. They possess a wide range of formulations and are often preferred for chronic pain management in conditions such as arthritis. In contrast, opioids represent the emerging segment, increasingly recognized for their potency in treating severe pain, particularly post-surgical or in cancer patients. The growing emphasis on pain relief standards in veterinary medicine has prompted veterinarians to explore opioid options more vigorously, highlighting the need for responsible prescribing practices and proper pain management protocols in veterinary care.

By Animal Type: Dogs (Largest) vs. Cats (Fastest-Growing)

In the Veterinary Pain Management Market, Dogs represent the largest segment, capturing a significant market share due to their commonality as pets and the high incidence of various health issues that require pain management. Cats follow closely behind, emerging as a rapidly growing segment influenced by increasing pet ownership rates and enhanced awareness of feline health needs. As a result, the dynamics between these two segments show a fascinating interplay of established dominance versus fast-paced growth.

Dogs (Dominant) vs. Cats (Emerging)

The dominance of the Dogs segment in the Veterinary Pain Management Market can be attributed to their greater population and higher likelihood of experiencing pain-related conditions, such as arthritis or post-surgical complications. Consequently, this segment benefits from a plethora of treatment options, ranging from medications to holistic approaches. On the other hand, the Cats segment, while currently smaller, is emerging robustly. Driven by changing consumer attitudes towards feline care and increased veterinary services dedicated to cats, this segment is gaining traction. As owners become more aware of pain management therapies tailored for cats, the segment's growth trajectory indicates a bright future alongside the established canine market.

By Route of Administration: Oral (Largest) vs. Injections (Fastest-Growing)

The Veterinary Pain Management Market shows a diverse distribution among its routes of administration, with oral administration holding the largest share. This method is favored due to its ease of use and non-invasive nature, making it popular among pet owners and veterinarians alike. In contrast, injections are gaining traction as a faster-acting alternative, which appeals to urgent care situations and critical pain management, reflecting an increasing inclination towards these forms of treatment in veterinary practices. Growth trends indicate a shift towards injections as the fastest-growing segment within the Veterinary Pain Management Market. The rising prevalence of acute pain conditions in animals and the demand for quicker relief solutions are significant drivers for this trend. Additionally, increasing investments in research and development are leading to innovative formulations that enhance the efficacy of both oral and injection routes, contributing to a competitive landscape in veterinary pain management solutions.

Oral (Dominant) vs. Injections (Emerging)

Oral administration methods dominate the Veterinary Pain Management Market due to their convenience and compliance advantages, allowing pet owners to easily administer medications without specialized training. This route ensures steady plasma levels of therapeutic agents while minimizing stress for the animal. Conversely, injections have emerged as a critical alternative, especially in emergency situations, where rapid analgesic effects are required. This route is gaining market share owing to advancements in injectable formulations, which provide sustained relief and reduce the frequency of administration. Overall, both routes cater to different needs in pain management, with oral methods leading in overall adoption and injections rising in importance.

By End User: Veterinary Hospitals (Largest) vs. Clinics (Fastest-Growing)

In the Veterinary Pain Management Market, the distribution of market share among various end users reveals a significant dominance of veterinary hospitals, which cater to a wide range of animals and often provide comprehensive pain management solutions. Clinics, while smaller in share compared to hospitals, are gaining traction due to their increased accessibility and focused services, addressing specific pain management needs for pets and specialized patients. Additionally, research institutes are integral to this segment as they drive innovation and advancements in pain management therapies. The growth of these segments is influenced by rising pet ownership, increased awareness of animal health, and a greater emphasis on preventive care, pushing clinics and hospitals to expand their veterinary pain management offerings to meet consumer demands.

Veterinary Hospitals (Dominant) vs. Clinics (Emerging)

Veterinary hospitals represent the dominant force in the Veterinary Pain Management Market, benefiting from their extensive resources and ability to provide a wide range of services. They often feature specialized departments that cater to specific pain management needs across various species, making them a go-to for comprehensive care. They have established trust and reputation in managing complex cases, which solidifies their market position. On the other hand, clinics are emerging as significant players in this landscape, characterized by their agility and tailored services. They offer convenience and quicker access to pain management solutions, appealing to a growing consumer base that prioritizes immediate care. As pet owners seek more personalized veterinary attention, clinics are increasingly adopting advanced pain management techniques, positioning themselves effectively to capture a larger market share.

Get more detailed insights about Veterinary Pain Management Market Research Report-Forecast to 2035

Regional Insights

North America : Market Leader in Innovation

North America is the largest market for veterinary pain management, supported by advanced veterinary infrastructure and strong demand in regions such as the United States veterinary pain management market, which contributes significantly to overall growth. The region benefits from advanced veterinary practices, increasing pet ownership, and a growing awareness of animal welfare. Regulatory support from agencies like the FDA enhances the market's growth, facilitating the approval of innovative pain management solutions. The United States and Canada are the leading countries in this region, with major players like Zoetis, Elanco, and Merck Animal Health driving competition. The presence of well-established veterinary clinics and hospitals further boosts demand for effective pain management products. The competitive landscape is characterized by continuous innovation and strategic partnerships among key players.

Europe : Emerging Market with Growth Potential

Europe accounts for around 30% of the global market share, contributing to the expansion of the global veterinary pain management market through increased regulatory support and innovation. The region is witnessing a rise in pet ownership and an increasing focus on animal health, driven by stringent regulations and a growing demand for effective pain management solutions. The European Medicines Agency (EMA) plays a crucial role in regulating veterinary medicines, ensuring safety and efficacy. Leading countries in Europe include Germany, France, and the UK, where companies like Boehringer Ingelheim and Vetoquinol are prominent. The competitive landscape is marked by a mix of established firms and emerging players, all striving to meet the evolving needs of veterinarians and pet owners. The emphasis on research and development is expected to further enhance market growth.

Asia-Pacific : Rapidly Growing Veterinary Sector

Asia-Pacific is an emerging powerhouse in the veterinary pain management market, holding approximately 20% of the global share. Asia-Pacific is an emerging powerhouse, driving growth in overall veterinary pain management market size through rising disposable incomes and expanding veterinary services. Regulatory bodies are becoming more active in approving veterinary products, which is expected to drive market expansion. Countries like China, Japan, and Australia are leading the charge, with key players such as MediVet and Elanco making significant inroads. The competitive landscape is evolving, with both local and international companies vying for market share. The increasing number of veterinary clinics and hospitals is further propelling the demand for effective pain management solutions.

Middle East and Africa : Untapped Market Potential

The Middle East and Africa represent an untapped market for veterinary pain management, accounting for about 5% of the global share. The region represents emerging opportunities within the broader veterinary pain management market landscape. Regulatory frameworks are still developing, but there is a growing interest in veterinary products that address pain management. Countries like South Africa and the UAE are at the forefront of this market, with local players and international companies like Virbac and Ceva Santé Animale expanding their presence. The competitive landscape is characterized by a mix of established firms and new entrants, all aiming to cater to the evolving needs of veterinarians and pet owners in the region.

Key Players and Competitive Insights

The Veterinary Pain Management Market is currently characterized by a dynamic competitive landscape shaped by increasing awareness of animal welfare and technological innovation. Strategic activities by key players continue to drive growth across the veterinary pain management market and reinforce evolving veterinary pain management market trends. Key players such as Zoetis (US), Boehringer Ingelheim (DE), and Elanco Animal Health (US) are strategically positioned to leverage innovation and expand their product portfolios. Zoetis (US) focuses on developing novel analgesics and anti-inflammatory medications, while Boehringer Ingelheim (DE) emphasizes partnerships with veterinary clinics to enhance service delivery. Elanco Animal Health (US) is actively pursuing mergers and acquisitions to bolster its market presence, indicating a trend towards consolidation in the sector. Collectively, these strategies contribute to a competitive environment that prioritizes innovation and customer-centric solutions. In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and enhance supply chain efficiency. The Veterinary Pain Management Market appears moderately fragmented, with several players vying for market share. However, the influence of major companies is substantial, as they set industry standards and drive technological advancements. This competitive structure suggests that while smaller firms may struggle to compete on scale, they can still carve out niches through specialized offerings or regional expertise.
In August Zoetis (US) announced the launch of a new pain management product specifically designed for post-operative care in canines. This strategic move not only addresses a critical need in veterinary medicine but also reinforces Zoetis's commitment to innovation in pain management solutions. The introduction of this product is likely to enhance the company's market share and strengthen its reputation as a leader in veterinary pharmaceuticals.
In September Boehringer Ingelheim (DE) expanded its partnership with veterinary clinics across Europe to provide comprehensive pain management training for veterinarians. This initiative underscores the company's focus on education and support, which may lead to improved treatment outcomes and increased loyalty among veterinary professionals. By investing in training, Boehringer Ingelheim (DE) positions itself as a trusted partner in the veterinary community, potentially enhancing its competitive edge.
In July Elanco Animal Health (US) completed the acquisition of a biotechnology firm specializing in pain management solutions for livestock. This acquisition is indicative of Elanco's strategy to diversify its product offerings and enter new market segments. By integrating innovative technologies from the acquired firm, Elanco (US) may enhance its competitive positioning and address a broader range of pain management needs across species.
As of October the Veterinary Pain Management Market is witnessing trends such as digitalization, sustainability, and the integration of artificial intelligence in product development. Strategic alliances among key players are shaping the competitive landscape, fostering collaboration that enhances innovation and market responsiveness. Looking ahead, it appears that competitive differentiation will increasingly hinge on technological advancements and supply chain reliability, rather than solely on price. This shift suggests a future where innovation and quality will be paramount in defining market leadership.

Key Companies in the Veterinary Pain Management Market include

Industry Developments

Recent developments in the global veterinary pain management market highlight increased innovation and expansion among key players, particularly in developing advanced therapies within the veterinary pain management drugs market. Companies like Vetoquinol and Elanco have been increasing their focus on developing advanced analgesic medications tailored for veterinary use. In April 2023, Zoetis announced the launch of a new pain management solution for dogs, illustrating the market's growth in addressing specific animal needs. Major current affairs reflect an increased awareness of animal welfare, with a greater emphasis being placed on pain management in veterinary practices across multiple regions.

Mergers and acquisitions have also been pivotal; for instance, in March 2023, Boehringer Ingelheim completed the acquisition of a promising pain management technology firm, indicative of strategic consolidation in the market. In the last couple of years, market growth has been significant, with a notable increase in funding allocated for Research and Development initiatives across various organizations, including Merial and Virbac. This rising trend supports an ongoing enhancement of available therapeutic options for pain relief in animals, underscoring the dynamic evolution of the industry.

Overall, the Global Veterinary Pain Management Market remains a focal point for innovation and strategic business activity.

Future Outlook

Veterinary Pain Management Market Future Outlook

The Veterinary Pain Management Market is projected to grow at a 6.42% CAGR from 2025 to 2035, driven by advancements in pain management technologies and increasing pet ownership.

New opportunities lie in:

  • <p>Development of telemedicine platforms for remote pain management consultations. Expansion of personalized pain management solutions tailored to specific animal breeds. Investment in research for innovative analgesics targeting chronic pain in pets.</p>

By 2035, the market is expected to be robust, reflecting significant advancements and increased adoption of pain management solutions.

Market Segmentation

Veterinary Pain Management Market End User Outlook

  • Veterinary Hospitals
  • Clinics
  • Research Institutes

Veterinary Pain Management Market Animal Type Outlook

  • Dogs
  • Cats
  • Horses
  • Livestock

Veterinary Pain Management Market Product Type Outlook

  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioids
  • Analgesics
  • Adjuvant Analgesics

Veterinary Pain Management Market Route of Administration Outlook

  • Oral
  • Injections
  • Transdermal
  • Topical

Report Scope

MARKET SIZE 2024 2.11(USD Billion)
MARKET SIZE 2025 2.246(USD Billion)
MARKET SIZE 2035 4.184(USD Billion)
COMPOUND ANNUAL GROWTH RATE (CAGR) 6.42% (2025 - 2035)
REPORT COVERAGE Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
BASE YEAR 2024
Market Forecast Period 2025 - 2035
Historical Data 2019 - 2024
Market Forecast Units USD Billion
Key Companies Profiled Zoetis (US), Boehringer Ingelheim (DE), Elanco Animal Health (US), Merck Animal Health (US), Vetoquinol (FR), Ceva Santé Animale (FR), Dechra Pharmaceuticals (GB), Virbac (FR), PetIQ (US), MediVet (AU)
Segments Covered Product Type, Animal Type, Route of Administration, End User, Regional
Key Market Opportunities Integration of telemedicine and digital therapeutics in the Veterinary Pain Management Market.
Key Market Dynamics Rising demand for innovative analgesics drives competitive dynamics in the Veterinary Pain Management Market.
Countries Covered North America, Europe, APAC, South America, MEA

FAQs

What is the projected market valuation of the Veterinary Pain Management Market by 2035?

<p>The Veterinary Pain Management Market is projected to reach approximately 4.184 USD Billion by 2035.</p>

What was the market valuation of the Veterinary Pain Management Market in 2024?

<p>In 2024, the market valuation of the Veterinary Pain Management Market was 2.11 USD Billion.</p>

What is the expected CAGR for the Veterinary Pain Management Market during the forecast period 2025 - 2035?

<p>The expected CAGR for the Veterinary Pain Management Market during the forecast period 2025 - 2035 is 6.42%.</p>

Which product type segment is anticipated to have the highest valuation by 2035?

<p>The Non-Steroidal Anti-Inflammatory Drugs segment is anticipated to reach approximately 1.68 USD Billion by 2035.</p>

How does the market for pain management in dogs compare to that in cats by 2035?

<p>By 2035, the market for pain management in dogs is expected to reach around 1.68 USD Billion, while the market for cats is projected to reach approximately 1.26 USD Billion.</p>

What are the key routes of administration for veterinary pain management products?

<p>The key routes of administration include Oral, Injections, Transdermal, and Topical, with Oral expected to reach 1.68 USD Billion by 2035.</p>

Which end user segment is projected to dominate the Veterinary Pain Management Market by 2035?

<p>Veterinary Hospitals are projected to dominate the market, with an expected valuation of approximately 1.68 USD Billion by 2035.</p>

Who are the leading companies in the Veterinary Pain Management Market?

<p>Key players in the Veterinary Pain Management Market include Zoetis, Boehringer Ingelheim, Elanco Animal Health, and Merck Animal Health.</p>

What is the expected growth trend for the Opioids segment in the Veterinary Pain Management Market?

<p>The Opioids segment is expected to grow to approximately 1.26 USD Billion by 2035, indicating a strong upward trend.</p>

How does the market for livestock pain management products compare to that for horses by 2035?

<p>By 2035, the market for livestock pain management products is projected to reach around 0.44 USD Billion, while the market for horses is expected to reach approximately 0.84 USD Billion.</p>

  1. SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. | 1.1 EXECUTIVE SUMMARY
    2. | | 1.1.1 Market Overview
    3. | | 1.1.2 Key Findings
    4. | | 1.1.3 Market Segmentation
    5. | | 1.1.4 Competitive Landscape
    6. | | 1.1.5 Challenges and Opportunities
    7. | | 1.1.6 Future Outlook
  2. SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. | 2.1 MARKET INTRODUCTION
    2. | | 2.1.1 Definition
    3. | | 2.1.2 Scope of the study
    4. | | | 2.1.2.1 Research Objective
    5. | | | 2.1.2.2 Assumption
    6. | | | 2.1.2.3 Limitations
    7. | 2.2 RESEARCH METHODOLOGY
    8. | | 2.2.1 Overview
    9. | | 2.2.2 Data Mining
    10. | | 2.2.3 Secondary Research
    11. | | 2.2.4 Primary Research
    12. | | | 2.2.4.1 Primary Interviews and Information Gathering Process
    13. | | | 2.2.4.2 Breakdown of Primary Respondents
    14. | | 2.2.5 Forecasting Model
    15. | | 2.2.6 Market Size Estimation
    16. | | | 2.2.6.1 Bottom-Up Approach
    17. | | | 2.2.6.2 Top-Down Approach
    18. | | 2.2.7 Data Triangulation
    19. | | 2.2.8 Validation
  3. SECTION III: QUALITATIVE ANALYSIS
    1. | 3.1 MARKET DYNAMICS
    2. | | 3.1.1 Overview
    3. | | 3.1.2 Drivers
    4. | | 3.1.3 Restraints
    5. | | 3.1.4 Opportunities
    6. | 3.2 MARKET FACTOR ANALYSIS
    7. | | 3.2.1 Value chain Analysis
    8. | | 3.2.2 Porter's Five Forces Analysis
    9. | | | 3.2.2.1 Bargaining Power of Suppliers
    10. | | | 3.2.2.2 Bargaining Power of Buyers
    11. | | | 3.2.2.3 Threat of New Entrants
    12. | | | 3.2.2.4 Threat of Substitutes
    13. | | | 3.2.2.5 Intensity of Rivalry
    14. | | 3.2.3 COVID-19 Impact Analysis
    15. | | | 3.2.3.1 Market Impact Analysis
    16. | | | 3.2.3.2 Regional Impact
    17. | | | 3.2.3.3 Opportunity and Threat Analysis
  4. SECTION IV: QUANTITATIVE ANALYSIS
    1. | 4.1 Healthcare, BY Product Type (USD Billion)
    2. | | 4.1.1 Non-Steroidal Anti-Inflammatory Drugs
    3. | | 4.1.2 Opioids
    4. | | 4.1.3 Analgesics
    5. | | 4.1.4 Adjuvant Analgesics
    6. | 4.2 Healthcare, BY Animal Type (USD Billion)
    7. | | 4.2.1 Dogs
    8. | | 4.2.2 Cats
    9. | | 4.2.3 Horses
    10. | | 4.2.4 Livestock
    11. | 4.3 Healthcare, BY Route of Administration (USD Billion)
    12. | | 4.3.1 Oral
    13. | | 4.3.2 Injections
    14. | | 4.3.3 Transdermal
    15. | | 4.3.4 Topical
    16. | 4.4 Healthcare, BY End User (USD Billion)
    17. | | 4.4.1 Veterinary Hospitals
    18. | | 4.4.2 Clinics
    19. | | 4.4.3 Research Institutes
    20. | 4.5 Healthcare, BY Region (USD Billion)
    21. | | 4.5.1 North America
    22. | | | 4.5.1.1 US
    23. | | | 4.5.1.2 Canada
    24. | | 4.5.2 Europe
    25. | | | 4.5.2.1 Germany
    26. | | | 4.5.2.2 UK
    27. | | | 4.5.2.3 France
    28. | | | 4.5.2.4 Russia
    29. | | | 4.5.2.5 Italy
    30. | | | 4.5.2.6 Spain
    31. | | | 4.5.2.7 Rest of Europe
    32. | | 4.5.3 APAC
    33. | | | 4.5.3.1 China
    34. | | | 4.5.3.2 India
    35. | | | 4.5.3.3 Japan
    36. | | | 4.5.3.4 South Korea
    37. | | | 4.5.3.5 Malaysia
    38. | | | 4.5.3.6 Thailand
    39. | | | 4.5.3.7 Indonesia
    40. | | | 4.5.3.8 Rest of APAC
    41. | | 4.5.4 South America
    42. | | | 4.5.4.1 Brazil
    43. | | | 4.5.4.2 Mexico
    44. | | | 4.5.4.3 Argentina
    45. | | | 4.5.4.4 Rest of South America
    46. | | 4.5.5 MEA
    47. | | | 4.5.5.1 GCC Countries
    48. | | | 4.5.5.2 South Africa
    49. | | | 4.5.5.3 Rest of MEA
  5. SECTION V: COMPETITIVE ANALYSIS
    1. | 5.1 Competitive Landscape
    2. | | 5.1.1 Overview
    3. | | 5.1.2 Competitive Analysis
    4. | | 5.1.3 Market share Analysis
    5. | | 5.1.4 Major Growth Strategy in the Healthcare
    6. | | 5.1.5 Competitive Benchmarking
    7. | | 5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
    8. | | 5.1.7 Key developments and growth strategies
    9. | | | 5.1.7.1 New Product Launch/Service Deployment
    10. | | | 5.1.7.2 Merger & Acquisitions
    11. | | | 5.1.7.3 Joint Ventures
    12. | | 5.1.8 Major Players Financial Matrix
    13. | | | 5.1.8.1 Sales and Operating Income
    14. | | | 5.1.8.2 Major Players R&D Expenditure. 2023
    15. | 5.2 Company Profiles
    16. | | 5.2.1 Zoetis (US)
    17. | | | 5.2.1.1 Financial Overview
    18. | | | 5.2.1.2 Products Offered
    19. | | | 5.2.1.3 Key Developments
    20. | | | 5.2.1.4 SWOT Analysis
    21. | | | 5.2.1.5 Key Strategies
    22. | | 5.2.2 Boehringer Ingelheim (DE)
    23. | | | 5.2.2.1 Financial Overview
    24. | | | 5.2.2.2 Products Offered
    25. | | | 5.2.2.3 Key Developments
    26. | | | 5.2.2.4 SWOT Analysis
    27. | | | 5.2.2.5 Key Strategies
    28. | | 5.2.3 Elanco Animal Health (US)
    29. | | | 5.2.3.1 Financial Overview
    30. | | | 5.2.3.2 Products Offered
    31. | | | 5.2.3.3 Key Developments
    32. | | | 5.2.3.4 SWOT Analysis
    33. | | | 5.2.3.5 Key Strategies
    34. | | 5.2.4 Merck Animal Health (US)
    35. | | | 5.2.4.1 Financial Overview
    36. | | | 5.2.4.2 Products Offered
    37. | | | 5.2.4.3 Key Developments
    38. | | | 5.2.4.4 SWOT Analysis
    39. | | | 5.2.4.5 Key Strategies
    40. | | 5.2.5 Vetoquinol (FR)
    41. | | | 5.2.5.1 Financial Overview
    42. | | | 5.2.5.2 Products Offered
    43. | | | 5.2.5.3 Key Developments
    44. | | | 5.2.5.4 SWOT Analysis
    45. | | | 5.2.5.5 Key Strategies
    46. | | 5.2.6 Ceva Santé Animale (FR)
    47. | | | 5.2.6.1 Financial Overview
    48. | | | 5.2.6.2 Products Offered
    49. | | | 5.2.6.3 Key Developments
    50. | | | 5.2.6.4 SWOT Analysis
    51. | | | 5.2.6.5 Key Strategies
    52. | | 5.2.7 Dechra Pharmaceuticals (GB)
    53. | | | 5.2.7.1 Financial Overview
    54. | | | 5.2.7.2 Products Offered
    55. | | | 5.2.7.3 Key Developments
    56. | | | 5.2.7.4 SWOT Analysis
    57. | | | 5.2.7.5 Key Strategies
    58. | | 5.2.8 Virbac (FR)
    59. | | | 5.2.8.1 Financial Overview
    60. | | | 5.2.8.2 Products Offered
    61. | | | 5.2.8.3 Key Developments
    62. | | | 5.2.8.4 SWOT Analysis
    63. | | | 5.2.8.5 Key Strategies
    64. | | 5.2.9 PetIQ (US)
    65. | | | 5.2.9.1 Financial Overview
    66. | | | 5.2.9.2 Products Offered
    67. | | | 5.2.9.3 Key Developments
    68. | | | 5.2.9.4 SWOT Analysis
    69. | | | 5.2.9.5 Key Strategies
    70. | | 5.2.10 MediVet (AU)
    71. | | | 5.2.10.1 Financial Overview
    72. | | | 5.2.10.2 Products Offered
    73. | | | 5.2.10.3 Key Developments
    74. | | | 5.2.10.4 SWOT Analysis
    75. | | | 5.2.10.5 Key Strategies
    76. | 5.3 Appendix
    77. | | 5.3.1 References
    78. | | 5.3.2 Related Reports
  6. LIST OF FIGURES
    1. | 6.1 MARKET SYNOPSIS
    2. | 6.2 NORTH AMERICA MARKET ANALYSIS
    3. | 6.3 US MARKET ANALYSIS BY PRODUCT TYPE
    4. | 6.4 US MARKET ANALYSIS BY ANIMAL TYPE
    5. | 6.5 US MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    6. | 6.6 US MARKET ANALYSIS BY END USER
    7. | 6.7 CANADA MARKET ANALYSIS BY PRODUCT TYPE
    8. | 6.8 CANADA MARKET ANALYSIS BY ANIMAL TYPE
    9. | 6.9 CANADA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    10. | 6.10 CANADA MARKET ANALYSIS BY END USER
    11. | 6.11 EUROPE MARKET ANALYSIS
    12. | 6.12 GERMANY MARKET ANALYSIS BY PRODUCT TYPE
    13. | 6.13 GERMANY MARKET ANALYSIS BY ANIMAL TYPE
    14. | 6.14 GERMANY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    15. | 6.15 GERMANY MARKET ANALYSIS BY END USER
    16. | 6.16 UK MARKET ANALYSIS BY PRODUCT TYPE
    17. | 6.17 UK MARKET ANALYSIS BY ANIMAL TYPE
    18. | 6.18 UK MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    19. | 6.19 UK MARKET ANALYSIS BY END USER
    20. | 6.20 FRANCE MARKET ANALYSIS BY PRODUCT TYPE
    21. | 6.21 FRANCE MARKET ANALYSIS BY ANIMAL TYPE
    22. | 6.22 FRANCE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    23. | 6.23 FRANCE MARKET ANALYSIS BY END USER
    24. | 6.24 RUSSIA MARKET ANALYSIS BY PRODUCT TYPE
    25. | 6.25 RUSSIA MARKET ANALYSIS BY ANIMAL TYPE
    26. | 6.26 RUSSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    27. | 6.27 RUSSIA MARKET ANALYSIS BY END USER
    28. | 6.28 ITALY MARKET ANALYSIS BY PRODUCT TYPE
    29. | 6.29 ITALY MARKET ANALYSIS BY ANIMAL TYPE
    30. | 6.30 ITALY MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    31. | 6.31 ITALY MARKET ANALYSIS BY END USER
    32. | 6.32 SPAIN MARKET ANALYSIS BY PRODUCT TYPE
    33. | 6.33 SPAIN MARKET ANALYSIS BY ANIMAL TYPE
    34. | 6.34 SPAIN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    35. | 6.35 SPAIN MARKET ANALYSIS BY END USER
    36. | 6.36 REST OF EUROPE MARKET ANALYSIS BY PRODUCT TYPE
    37. | 6.37 REST OF EUROPE MARKET ANALYSIS BY ANIMAL TYPE
    38. | 6.38 REST OF EUROPE MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    39. | 6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
    40. | 6.40 APAC MARKET ANALYSIS
    41. | 6.41 CHINA MARKET ANALYSIS BY PRODUCT TYPE
    42. | 6.42 CHINA MARKET ANALYSIS BY ANIMAL TYPE
    43. | 6.43 CHINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    44. | 6.44 CHINA MARKET ANALYSIS BY END USER
    45. | 6.45 INDIA MARKET ANALYSIS BY PRODUCT TYPE
    46. | 6.46 INDIA MARKET ANALYSIS BY ANIMAL TYPE
    47. | 6.47 INDIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    48. | 6.48 INDIA MARKET ANALYSIS BY END USER
    49. | 6.49 JAPAN MARKET ANALYSIS BY PRODUCT TYPE
    50. | 6.50 JAPAN MARKET ANALYSIS BY ANIMAL TYPE
    51. | 6.51 JAPAN MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    52. | 6.52 JAPAN MARKET ANALYSIS BY END USER
    53. | 6.53 SOUTH KOREA MARKET ANALYSIS BY PRODUCT TYPE
    54. | 6.54 SOUTH KOREA MARKET ANALYSIS BY ANIMAL TYPE
    55. | 6.55 SOUTH KOREA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    56. | 6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
    57. | 6.57 MALAYSIA MARKET ANALYSIS BY PRODUCT TYPE
    58. | 6.58 MALAYSIA MARKET ANALYSIS BY ANIMAL TYPE
    59. | 6.59 MALAYSIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    60. | 6.60 MALAYSIA MARKET ANALYSIS BY END USER
    61. | 6.61 THAILAND MARKET ANALYSIS BY PRODUCT TYPE
    62. | 6.62 THAILAND MARKET ANALYSIS BY ANIMAL TYPE
    63. | 6.63 THAILAND MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    64. | 6.64 THAILAND MARKET ANALYSIS BY END USER
    65. | 6.65 INDONESIA MARKET ANALYSIS BY PRODUCT TYPE
    66. | 6.66 INDONESIA MARKET ANALYSIS BY ANIMAL TYPE
    67. | 6.67 INDONESIA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    68. | 6.68 INDONESIA MARKET ANALYSIS BY END USER
    69. | 6.69 REST OF APAC MARKET ANALYSIS BY PRODUCT TYPE
    70. | 6.70 REST OF APAC MARKET ANALYSIS BY ANIMAL TYPE
    71. | 6.71 REST OF APAC MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    72. | 6.72 REST OF APAC MARKET ANALYSIS BY END USER
    73. | 6.73 SOUTH AMERICA MARKET ANALYSIS
    74. | 6.74 BRAZIL MARKET ANALYSIS BY PRODUCT TYPE
    75. | 6.75 BRAZIL MARKET ANALYSIS BY ANIMAL TYPE
    76. | 6.76 BRAZIL MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    77. | 6.77 BRAZIL MARKET ANALYSIS BY END USER
    78. | 6.78 MEXICO MARKET ANALYSIS BY PRODUCT TYPE
    79. | 6.79 MEXICO MARKET ANALYSIS BY ANIMAL TYPE
    80. | 6.80 MEXICO MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    81. | 6.81 MEXICO MARKET ANALYSIS BY END USER
    82. | 6.82 ARGENTINA MARKET ANALYSIS BY PRODUCT TYPE
    83. | 6.83 ARGENTINA MARKET ANALYSIS BY ANIMAL TYPE
    84. | 6.84 ARGENTINA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    85. | 6.85 ARGENTINA MARKET ANALYSIS BY END USER
    86. | 6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY PRODUCT TYPE
    87. | 6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY ANIMAL TYPE
    88. | 6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    89. | 6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
    90. | 6.90 MEA MARKET ANALYSIS
    91. | 6.91 GCC COUNTRIES MARKET ANALYSIS BY PRODUCT TYPE
    92. | 6.92 GCC COUNTRIES MARKET ANALYSIS BY ANIMAL TYPE
    93. | 6.93 GCC COUNTRIES MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    94. | 6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
    95. | 6.95 SOUTH AFRICA MARKET ANALYSIS BY PRODUCT TYPE
    96. | 6.96 SOUTH AFRICA MARKET ANALYSIS BY ANIMAL TYPE
    97. | 6.97 SOUTH AFRICA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    98. | 6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
    99. | 6.99 REST OF MEA MARKET ANALYSIS BY PRODUCT TYPE
    100. | 6.100 REST OF MEA MARKET ANALYSIS BY ANIMAL TYPE
    101. | 6.101 REST OF MEA MARKET ANALYSIS BY ROUTE OF ADMINISTRATION
    102. | 6.102 REST OF MEA MARKET ANALYSIS BY END USER
    103. | 6.103 KEY BUYING CRITERIA OF HEALTHCARE
    104. | 6.104 RESEARCH PROCESS OF MRFR
    105. | 6.105 DRO ANALYSIS OF HEALTHCARE
    106. | 6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
    107. | 6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
    108. | 6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
    109. | 6.109 HEALTHCARE, BY PRODUCT TYPE, 2024 (% SHARE)
    110. | 6.110 HEALTHCARE, BY PRODUCT TYPE, 2024 TO 2035 (USD Billion)
    111. | 6.111 HEALTHCARE, BY ANIMAL TYPE, 2024 (% SHARE)
    112. | 6.112 HEALTHCARE, BY ANIMAL TYPE, 2024 TO 2035 (USD Billion)
    113. | 6.113 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 (% SHARE)
    114. | 6.114 HEALTHCARE, BY ROUTE OF ADMINISTRATION, 2024 TO 2035 (USD Billion)
    115. | 6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
    116. | 6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
    117. | 6.117 BENCHMARKING OF MAJOR COMPETITORS
  7. LIST OF TABLES
    1. | 7.1 LIST OF ASSUMPTIONS
    2. | | 7.1.1
    3. | 7.2 North America MARKET SIZE ESTIMATES; FORECAST
    4. | | 7.2.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    5. | | 7.2.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    6. | | 7.2.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    7. | | 7.2.4 BY END USER, 2025-2035 (USD Billion)
    8. | 7.3 US MARKET SIZE ESTIMATES; FORECAST
    9. | | 7.3.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    10. | | 7.3.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    11. | | 7.3.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    12. | | 7.3.4 BY END USER, 2025-2035 (USD Billion)
    13. | 7.4 Canada MARKET SIZE ESTIMATES; FORECAST
    14. | | 7.4.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    15. | | 7.4.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    16. | | 7.4.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    17. | | 7.4.4 BY END USER, 2025-2035 (USD Billion)
    18. | 7.5 Europe MARKET SIZE ESTIMATES; FORECAST
    19. | | 7.5.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    20. | | 7.5.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    21. | | 7.5.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    22. | | 7.5.4 BY END USER, 2025-2035 (USD Billion)
    23. | 7.6 Germany MARKET SIZE ESTIMATES; FORECAST
    24. | | 7.6.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    25. | | 7.6.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    26. | | 7.6.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    27. | | 7.6.4 BY END USER, 2025-2035 (USD Billion)
    28. | 7.7 UK MARKET SIZE ESTIMATES; FORECAST
    29. | | 7.7.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    30. | | 7.7.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    31. | | 7.7.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    32. | | 7.7.4 BY END USER, 2025-2035 (USD Billion)
    33. | 7.8 France MARKET SIZE ESTIMATES; FORECAST
    34. | | 7.8.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    35. | | 7.8.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    36. | | 7.8.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    37. | | 7.8.4 BY END USER, 2025-2035 (USD Billion)
    38. | 7.9 Russia MARKET SIZE ESTIMATES; FORECAST
    39. | | 7.9.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    40. | | 7.9.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    41. | | 7.9.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    42. | | 7.9.4 BY END USER, 2025-2035 (USD Billion)
    43. | 7.10 Italy MARKET SIZE ESTIMATES; FORECAST
    44. | | 7.10.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    45. | | 7.10.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    46. | | 7.10.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    47. | | 7.10.4 BY END USER, 2025-2035 (USD Billion)
    48. | 7.11 Spain MARKET SIZE ESTIMATES; FORECAST
    49. | | 7.11.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    50. | | 7.11.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    51. | | 7.11.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    52. | | 7.11.4 BY END USER, 2025-2035 (USD Billion)
    53. | 7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
    54. | | 7.12.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    55. | | 7.12.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    56. | | 7.12.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    57. | | 7.12.4 BY END USER, 2025-2035 (USD Billion)
    58. | 7.13 APAC MARKET SIZE ESTIMATES; FORECAST
    59. | | 7.13.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    60. | | 7.13.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    61. | | 7.13.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    62. | | 7.13.4 BY END USER, 2025-2035 (USD Billion)
    63. | 7.14 China MARKET SIZE ESTIMATES; FORECAST
    64. | | 7.14.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    65. | | 7.14.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    66. | | 7.14.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    67. | | 7.14.4 BY END USER, 2025-2035 (USD Billion)
    68. | 7.15 India MARKET SIZE ESTIMATES; FORECAST
    69. | | 7.15.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    70. | | 7.15.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    71. | | 7.15.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    72. | | 7.15.4 BY END USER, 2025-2035 (USD Billion)
    73. | 7.16 Japan MARKET SIZE ESTIMATES; FORECAST
    74. | | 7.16.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    75. | | 7.16.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    76. | | 7.16.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    77. | | 7.16.4 BY END USER, 2025-2035 (USD Billion)
    78. | 7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
    79. | | 7.17.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    80. | | 7.17.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    81. | | 7.17.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    82. | | 7.17.4 BY END USER, 2025-2035 (USD Billion)
    83. | 7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
    84. | | 7.18.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    85. | | 7.18.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    86. | | 7.18.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    87. | | 7.18.4 BY END USER, 2025-2035 (USD Billion)
    88. | 7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
    89. | | 7.19.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    90. | | 7.19.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    91. | | 7.19.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    92. | | 7.19.4 BY END USER, 2025-2035 (USD Billion)
    93. | 7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
    94. | | 7.20.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    95. | | 7.20.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    96. | | 7.20.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    97. | | 7.20.4 BY END USER, 2025-2035 (USD Billion)
    98. | 7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
    99. | | 7.21.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    100. | | 7.21.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    101. | | 7.21.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    102. | | 7.21.4 BY END USER, 2025-2035 (USD Billion)
    103. | 7.22 South America MARKET SIZE ESTIMATES; FORECAST
    104. | | 7.22.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    105. | | 7.22.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    106. | | 7.22.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    107. | | 7.22.4 BY END USER, 2025-2035 (USD Billion)
    108. | 7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
    109. | | 7.23.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    110. | | 7.23.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    111. | | 7.23.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    112. | | 7.23.4 BY END USER, 2025-2035 (USD Billion)
    113. | 7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
    114. | | 7.24.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    115. | | 7.24.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    116. | | 7.24.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    117. | | 7.24.4 BY END USER, 2025-2035 (USD Billion)
    118. | 7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
    119. | | 7.25.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    120. | | 7.25.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    121. | | 7.25.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    122. | | 7.25.4 BY END USER, 2025-2035 (USD Billion)
    123. | 7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
    124. | | 7.26.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    125. | | 7.26.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    126. | | 7.26.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    127. | | 7.26.4 BY END USER, 2025-2035 (USD Billion)
    128. | 7.27 MEA MARKET SIZE ESTIMATES; FORECAST
    129. | | 7.27.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    130. | | 7.27.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    131. | | 7.27.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    132. | | 7.27.4 BY END USER, 2025-2035 (USD Billion)
    133. | 7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
    134. | | 7.28.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    135. | | 7.28.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    136. | | 7.28.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    137. | | 7.28.4 BY END USER, 2025-2035 (USD Billion)
    138. | 7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
    139. | | 7.29.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    140. | | 7.29.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    141. | | 7.29.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    142. | | 7.29.4 BY END USER, 2025-2035 (USD Billion)
    143. | 7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
    144. | | 7.30.1 BY PRODUCT TYPE, 2025-2035 (USD Billion)
    145. | | 7.30.2 BY ANIMAL TYPE, 2025-2035 (USD Billion)
    146. | | 7.30.3 BY ROUTE OF ADMINISTRATION, 2025-2035 (USD Billion)
    147. | | 7.30.4 BY END USER, 2025-2035 (USD Billion)
    148. | 7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
    149. | | 7.31.1
    150. | 7.32 ACQUISITION/PARTNERSHIP
    151. | | 7.32.1

Healthcare Market Segmentation

Healthcare By Product Type (USD Billion, 2025-2035)

  • Non-Steroidal Anti-Inflammatory Drugs
  • Opioids
  • Analgesics
  • Adjuvant Analgesics

Healthcare By Animal Type (USD Billion, 2025-2035)

  • Dogs
  • Cats
  • Horses
  • Livestock

Healthcare By Route of Administration (USD Billion, 2025-2035)

  • Oral
  • Injections
  • Transdermal
  • Topical

Healthcare By End User (USD Billion, 2025-2035)

  • Veterinary Hospitals
  • Clinics
  • Research Institutes
Infographic

Free Sample Request

Kindly complete the form below to receive a free sample of this Report

Get Free Sample

Related Reports

Regional Reports
Country Reports

Customer Strories

Customer Stories
Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Compare Licence

×
Features License Type
Single User Multiuser License Enterprise User
Price $4,950 $5,950 $7,250
Maximum User Access Limit 1 User Upto 10 Users Unrestricted Access Throughout the Organization
Free Customization ✓ ✓ ✓
Direct Access to Analyst ✓ ✓ ✓
Deliverable Format ✓ ✓ ✓
Platform Access ✗ ✗ ✓
Discount on Next Purchase 10% 15% 15%
Printable Versions ✗ ✗ ✓